Critically ill patients present with complex illnesses that are treated with multiple interventions including medications, invasive procedures, blood product transfusion and utilization of devices. In some circumstances, the zeal for the use of technologies and medications may not be balanced by a thorough appreciation of benefits and risks. One intervention that has become prevalent in the intensive care unit (ICU) is administration of proton pump inhibitors (PPIs). There are two aspects of this therapy that are concerning: overuse of PPIs for acid stress ulcer prophylaxis and the potential contribution to C. difficile infection.
The frequency of clinically significant bleeding in ICU patients due to stress ulcers has been reported as approximately 1.5-4%. The risk of significant bleeding in critically ill patients is probably less today due to interventions such as early use of enteral nutrition and improved resuscitation to prevent and treat hypoperfusion. Studies from the 1990s showed that major risk factors for significant gastrointestinal bleeding in ICU patients are mechanical ventilation greater than 48 h, acute hepatic failure and coagulopathy (international normalized ratio >1.5 or partial thromboplastin time >2 times control value). [1, 2] Additional risk factors that have been suggested include acute and chronic renal failure, sepsis, hypotension, alcohol abuse, absence of enteral nutrition, severe head injury, extensive burns and high dose corticosteroids (>250 mg hydrocortisone or equivalent/day). Most studies of risk factors suffer from small sample size and methodological weaknesses.
Currently, stress ulcer prophylaxis may be prescribed inappropriately to ICU patients. An Australian study found an increase in stress ulcer prophylaxis for ICU patients from 67% in 1997 to 86% in 2005. [3] In the same time period, the use of PPI for stress ulcer prophylaxis increased from 13% to 45%. Stress ulcer prophylaxis has been used unnecessarily in ICU patients without significant risk of bleeding [4] and some physicians even prescribe therapy in all ICU patients regardless of risk [5] .
PPI use has been associated with a variety of adverse effects. Perhaps the strongest relationship exists between PPI use and development of C. difficile infection. Several studies have also suggested an increased incidence of communityacquired [6] and nosocomial pneumonia [7] . Long-term use of PPIs can contribute to hypomagnesemia and vitamin B12 deficiency [8] .
There is no doubt that incidence, severity and healthcare burden of C. difficile infection have been increasing in hospitals, nursing homes and the outpatient setting. Although no randomized controlled studies have been reported, recent meta-analyses of case-control and cohort studies reached the same conclusion: PPI use increases the probability of C. difficile infection almost twofold. [9] [10] [11] In addition, there may be an increased risk of recurrent infection if PPIs are administered. [10] Not surprisingly, the risk of C. difficile infection is even higher when PPIs and antibiotics are used concomitantly. [10] A recent study suggests that an increased risk of C. difficile infection may be apparent when PPI use exceeds 2 days in patients without a prior hospitalization and 1 day in patients with a prior admission. [12] I believe it is time to re-examine the use of stress ulcer prophylaxis and the use of PPIs in particular in critically ill patients. PPIs should only be considered for ICU patients with a high risk of stress ulcer bleeding. Once the risk of bleeding has decreased, PPI use should be discontinued. Every effort should be made to discontinue PPI use in the setting of C. difficile infection. Unfortunately, PPI use started in the ICU is often continued as the patient transitions to the general floor and discharge. PPI use in ICU patients should be reassessed for appropriate continuation before transfer to another level of care. Perhaps PPIs should be added to the daily checklist of items to discontinue or avoid in ICU patients similar to interventions such as urinary catheters, central lines, and sedation.
The bottom line is that less use of PPIs in critically ill patients may be beneficial.
